We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.

Provan, D., Butler, T., Evangelista, M., Amadori, S., Newland, A., Stasi, R. (2007). Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. HAEMATOLOGICA, 92, 1695-1698 [10.3324/haematol.11709].

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

AMADORI, SERGIO;
2007-01-01

Abstract

We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.
2007
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - MALATTIE DEL SANGUE
English
Autoimmune disease; Cytopenias; Low dose; Rituximab
Provan, D., Butler, T., Evangelista, M., Amadori, S., Newland, A., Stasi, R. (2007). Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. HAEMATOLOGICA, 92, 1695-1698 [10.3324/haematol.11709].
Provan, D; Butler, T; Evangelista, M; Amadori, S; Newland, A; Stasi, R
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/37795
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 113
  • ???jsp.display-item.citation.isi??? 93
social impact